person

Mario B.

Country
Italy
Department
Nephrology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
12
Sites with multiple studies

Has run more than one trial at 12 of 113 partner sites.

Specializations

Nephrology

The investigator specializes in IgA nephropathy (IgAN) treatment approaches, with particular attention to targeted therapies based on kidney biopsy findings. Their research encompasses evaluation of early therapeutic interventions and assessment of various treatment combinations including corticosteroid therapy and RASD inhibitors.

  • IgA Nephropathy Management
  • Renal Biopsy Analysis
  • Proteinuria Treatment

Their work extends to investigating innovative therapeutic approaches for different stages of renal lesions.

Dialysis Innovation

The investigator focuses on advancing peritoneal dialysis treatments, particularly through the evaluation of novel dialysis solutions. Their research includes the development and assessment of glucose-sparing experimental solutions for patients with end-stage kidney disease.

  • Peritoneal Dialysis Optimization
  • Alternative Dialysis Solutions
  • Urea Clearance Assessment

Their expertise includes evaluating the efficacy and safety of innovative dialysis solutions.

Cardio-Renal Medicine

The investigator explores the intersection of cardiac and renal conditions, particularly focusing on cardio-renal syndrome. Their research involves innovative approaches to managing congestive heart failure through peritoneal ultrafiltration techniques.

  • Heart Failure Management
  • Ultrafiltration Therapy
  • Cardio-Renal Interventions

Their work aims to prevent heart failure exacerbation through novel treatment approaches.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.